Complete financial analysis of PT Enseval Putera Megatrading Tbk. (EPMT.JK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PT Enseval Putera Megatrading Tbk., a leading company in the Medical – Distribution industry within the Healthcare sector.
- Canfor Pulp Products Inc. (CFPUF) Income Statement Analysis – Financial Results
- MillerKnoll, Inc. (MLKN) Income Statement Analysis – Financial Results
- iMotion Automotive Tech (1274.HK) Income Statement Analysis – Financial Results
- IG Group Holdings plc (IGGHY) Income Statement Analysis – Financial Results
- Uponor Oyj (UPONOR.HE) Income Statement Analysis – Financial Results
PT Enseval Putera Megatrading Tbk. (EPMT.JK)
About PT Enseval Putera Megatrading Tbk.
PT Enseval Putera Megatrading Tbk., together with its subsidiaries, engages in the distribution and supply of pharmaceutical products in Indonesia. The company operates through three segments: Pharmaceutical, Consumer Products, and Others. It also trades in medical and laboratory equipment and supplies; operates health care clinics; and offers dental and other equipment, as well as calibration services. In addition, the company engages in the trading of raw materials for pharmaceutical products; consumable products for hemodialysis therapy; and food and beverages. Further, it offers warehousing services, including chiller, cool, and ambient rooms, as well as container chiller. The company was formerly known as PT Arya Gupta Cempaka and changed its name to PT Enseval Putera Megatrading Tbk. in August 1993. The company was incorporated in 1973 and is headquartered in East Jakarta, Indonesia. PT Enseval Putera Megatrading Tbk. is a subsidiary of PT Kalbe Farma Tbk.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28,507.87B | 28,027.49B | 25,673.76B | 22,545.42B | 22,226.91B | 20,604.49B | 19,669.10B | 18,936.24B | 17,476.10B | 17,011.55B | 15,623.24B | 13,373.03B | 10,610.08B |
| Cost of Revenue | 25,594.51B | 25,063.49B | 22,868.62B | 20,086.79B | 19,771.99B | 18,207.49B | 17,534.91B | 16,759.00B | 15,366.26B | 15,081.77B | 13,859.94B | 11,936.61B | 9,400.74B |
| Gross Profit | 2,913.36B | 2,963.99B | 2,805.13B | 2,458.63B | 2,454.92B | 2,397.00B | 2,134.19B | 2,177.24B | 2,109.84B | 1,929.78B | 1,763.30B | 1,436.42B | 1,209.34B |
| Gross Profit Ratio | 10.22% | 10.58% | 10.93% | 10.91% | 11.04% | 11.63% | 10.85% | 11.50% | 12.07% | 11.34% | 11.29% | 10.74% | 11.40% |
| Research & Development | 2.62B | 2.07B | 1.97B | 2.66B | 2.43B | 4.77B | 1.01B | 1.29B | 3.29B | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 87.87B | 72.58B | 67.21B | 67.39B | 73.55B | 66.24B | 63.92B | 63.74B | 67.90B | 69.02B | 95.75B | 74.83B | 67.16B |
| Selling & Marketing | 823.40B | 763.65B | 706.10B | 637.70B | 720.71B | 608.01B | 566.50B | 563.57B | 482.27B | 415.76B | 374.76B | 319.24B | 233.31B |
| SG&A | 1,989.43B | 836.22B | 773.31B | 705.10B | 794.25B | 674.25B | 630.42B | 627.31B | 550.17B | 484.79B | 470.51B | 394.07B | 300.47B |
| Other Expenses | 0.00 | 1,030.16B | 995.71B | 983.33B | 911.24B | 876.92B | 858.55B | -14.58B | -8.48B | 5.09B | 4.32B | 3.50B | 1.70B |
| Operating Expenses | 1,992.05B | 1,868.46B | 1,770.99B | 1,691.09B | 1,707.92B | 1,555.93B | 1,489.98B | 1,493.76B | 1,403.02B | 1,284.93B | 1,141.65B | 922.56B | 764.75B |
| Cost & Expenses | 27,635.73B | 26,931.95B | 24,639.61B | 21,777.88B | 21,479.92B | 19,763.42B | 19,024.89B | 18,252.76B | 16,769.28B | 16,366.70B | 15,001.59B | 12,859.18B | 10,165.49B |
| Interest Income | 12.35B | 19.32B | 31.70B | 43.49B | 55.80B | 54.47B | 51.34B | 71.01B | 49.81B | 23.77B | 17.29B | 20.17B | 25.70B |
| Interest Expense | 20.75B | 5.35B | 3.20B | 10.85B | 6.16B | 5.39B | 9.92B | 10.76B | 13.04B | 15.43B | 13.28B | 9.33B | 8.42B |
| Depreciation & Amortization | 169.62B | 173.80B | 179.86B | 162.82B | 128.11B | 127.26B | 120.79B | 126.79B | 129.08B | 115.22B | 95.98B | 80.50B | 68.71B |
| EBITDA | 1,072.75B | 1,281.12B | 1,273.92B | 1,047.28B | 935.66B | 962.10B | 765.14B | 883.13B | 866.46B | 782.78B | 732.04B | 629.85B | 539.87B |
| EBITDA Ratio | 3.76% | 4.49% | 4.79% | 4.39% | 4.19% | 4.86% | 4.10% | 4.64% | 4.96% | 4.60% | 4.56% | 4.62% | 5.07% |
| Operating Income | 905.25B | 1,084.61B | 1,050.48B | 826.74B | 802.25B | 873.91B | 684.88B | 752.20B | 737.38B | 667.56B | 616.92B | 536.83B | 469.02B |
| Operating Income Ratio | 3.18% | 3.87% | 4.09% | 3.67% | 3.61% | 4.24% | 3.48% | 3.97% | 4.22% | 3.92% | 3.95% | 4.01% | 4.42% |
| Total Other Income/Expenses | -16.68B | -2.02B | 48.05B | 46.87B | -857.37M | -5.67B | -127.12M | -6.62B | -474.88M | 48.26B | 1.14B | 3.19B | -6.27B |
| Income Before Tax | 888.57B | 1,096.53B | 1,083.96B | 873.61B | 801.39B | 868.23B | 684.76B | 745.58B | 736.90B | 687.17B | 622.78B | 540.02B | 462.74B |
| Income Before Tax Ratio | 3.12% | 3.91% | 4.22% | 3.87% | 3.61% | 4.21% | 3.48% | 3.94% | 4.22% | 4.04% | 3.99% | 4.04% | 4.36% |
| Income Tax Expense | 200.20B | 253.94B | 237.72B | 193.74B | 220.58B | 214.98B | 166.92B | 189.46B | 189.73B | 176.51B | 158.41B | 137.25B | 111.70B |
| Net Income | 688.50B | 847.53B | 847.88B | 680.60B | 580.63B | 653.06B | 517.67B | 556.03B | 547.12B | 510.61B | 464.32B | 402.75B | 351.04B |
| Net Income Ratio | 2.42% | 3.02% | 3.30% | 3.02% | 2.61% | 3.17% | 2.63% | 2.94% | 3.13% | 3.00% | 2.97% | 3.01% | 3.31% |
| EPS | 254.19 | 312.90 | 313.03 | 251.27 | 214.36 | 241.10 | 191.00 | 205.00 | 202.00 | 189.00 | 171.00 | 149.00 | 135.00 |
| EPS Diluted | 254.19 | 312.90 | 313.03 | 251.27 | 214.36 | 241.10 | 191.00 | 205.00 | 202.00 | 189.00 | 171.00 | 149.00 | 135.00 |
| Weighted Avg Shares Out | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.60B |
| Weighted Avg Shares Out (Dil) | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.71B | 2.60B |
Source: https://incomestatements.info
Category: Stock Reports